Astragalus Polysaccharides

Supplement

Astragalus Polysaccharides is retained as a catalog identity with independently verified primary-literature context. No qualified exposure model, dose recommendation, efficacy claim, or safety claim is provided.

Pharmacokinetic model

A route-level PK model for astragalus polysaccharides is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.

Key facts

Category
Supplement
Suggested cadence
once daily

Research behind this entry

  1. Astragalus polysaccharides repress myocardial lipotoxicity in a PPARalpha-dependent manner in vitro and in vivo in mice. Chen W, Lai Y, Wang L, Xia Y, Chen W, Zhao X, Yu M, Li Y, Zhang Y, Ye H · Journal of diabetes and its complications, 2015 DOI

    This citation reports a laboratory or cell study involving Astragalus Polysaccharides. It does not establish a qualified human dose, safety profile, efficacy claim, or pharmacokinetic route for this catalog record.

1 published study referenced in the app, each with a plain-language summary.